Home › Research › Disease mechanisms
Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease
Muzi Du, Suleyman C. Akerman, Charlotte M. Fare, Linhao Ruan, Svetlana Vidensky, Lyudmila Mamedova, Katie K. Koo, Joshua Y. Lee et al.. Acta Neuropathologica Communications, 2025-08-09
Topic: Brain proteins, microglia and lab models
Plain-language summary
TMEM106B is a lysosome/late endosome protein that is a potent genetic modifier of multiple neurodegenerative diseases as well as general aging. Recently, TMEM106B was shown to form insoluble aggregates in postmortem human brain tissue, drawing attention to TMEM106B pathology and the potential role of TMEM106B aggregation in disease. In the context of neurodegenerative diseases, TMEM106B has been studied in vivo using animal models of neurodegeneration, but these studies rely on overexpression or knockdown approaches. To date, endogenous TMEM106B pathology and its relationship to known canonical pathology in animal models has not been reported. Here, we analyze histological patterns of the endogenous TMEM106B protein in murine models of C9ORF72-related amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD), SOD1-related ALS, and tauopathy using an extensively validated TMEM106B antibody. We found profound correlations between the endogenous TMEM106B protein with known TDP-43 and tau pathology in murine models of C9-ALS/FTD and tauopathy, respectively. By using an antibody previously shown to recognize the pathologic TMEM106B C-terminal fragments, we then performed a similar analysis on postmortem brain tissues from patients with C9-ALS/FTD, Alzheimer's disease (AD), and AD with limbic-predominant age-related TDP-43 encephalopathy (AD/LATE). Convergent evidence from both murine models and human patients links TMEM106B to TDP-43 nuclear clearance at the cellular level in C9-ALS. By characterizing endogenous TMEM106B in mice and human postmortem tissue, our work reveals essential considerations that must be taken when analyzing data from in vivo mouse studies and elucidates new insights supporting the involvement of TMEM106B in the pathogenesis and progression of multiple neurodegenerative diseases.
What this study adds
Evidence grade: Low
In mouse models of C9-ALS/FTD and tauopathy, endogenous TMEM106B protein correlated with known TDP-43 and tau pathology, and similar analysis was done on postmortem human brain tissue from C9-ALS/FTD, Alzheimer's disease and AD/LATE. This is animal and autopsy research describing pathology and does not test a treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Du, M., Akerman, S. C., Fare, C. M., Ruan, L., Vidensky, S., Mamedova, L., et al. (2025). Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-025-02087-9
Vancouver
Du M, Akerman SC, Fare CM, Ruan L, Vidensky S, Mamedova L, et al. Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease. Acta Neuropathologica Communications. 2025. doi:10.1186/s40478-025-02087-9. PMID: 40783546.
BibTeX
@article{du2025-40783546,
author = {Du, Muzi and Akerman, Suleyman C. and Fare, Charlotte M. and Ruan, Linhao and Vidensky, Svetlana and Mamedova, Lyudmila and Koo, Katie K. and Lee, Joshua Y. and others},
title = {{Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease}},
journal = {Acta Neuropathologica Communications},
year = {2025},
doi = {10.1186/s40478-025-02087-9},
pmid = {40783546},
url = {https://doi.org/10.1186/s40478-025-02087-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We found profound correlations between the endogenous TMEM106B protein with known TDP-43 and tau pathology in murine models of C9-ALS/FTD and tauopathy, respectively.
Why it matters
In mouse models of C9-ALS/FTD and tauopathy, endogenous TMEM106B protein correlated with known TDP-43 and tau pathology, and similar analysis was done on postmortem human brain tissue from C9-ALS/FTD, Alzheimer's disease and AD/LATE. This is animal and autopsy research describing pathology and does not test a treatment.
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta Neuropathologica Communications) |
| Journal's citation record | 1 / 4 | Acta Neuropathologica Communications: journal h-index 129 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “murine”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Jeffrey D. Rothstein: h-index 118 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40783546) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s40478-025-02087-9
- PubMed: 40783546
- Original source →
- Free full text: Acta Neuropathologica Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Disease mechanisms from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.